NRJ:PA:PA- (EUR)

ETF | Others |

Last Closing

USD 26.155

Change

+0.06 (+0.21)%

Market Cap

USD 0.56B

Volume

411.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.17 (-0.39%)

USD 56.03B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-1.80 (-0.34%)

USD 13.60B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-2.41 (-0.64%)

USD 11.29B
WRD:PA HSBC MSCI World UCITS ETF

-0.15 (-0.45%)

USD 11.04B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-0.45 (-0.17%)

USD 10.45B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-2.55 (-0.55%)

USD 7.99B
WLD:PA Lyxor UCITS MSCI World D-EUR

-1.70 (-0.50%)

USD 7.49B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

+0.08 (+1.22%)

USD 7.42B
HHH:PA HSBC S&P 500 UCITS ETF

-0.20 (-0.37%)

USD 7.22B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

-0.66 (-0.80%)

USD 5.38B

ETFs Containing NRJ:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.59% 45% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.59% 43% F 43% F
Trailing 12 Months  
Capital Gain -8.26% 6% D- 32% F
Dividend Return 0.67% 4% F 4% F
Total Return -7.59% 7% C- 32% F
Trailing 5 Years  
Capital Gain -10.60% 12% F 31% F
Dividend Return 3.14% 4% F 7% C-
Total Return -7.45% 12% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -6.69% 5% F 24% F
Dividend Return -6.31% 53% F 23% F
Total Return 0.38% 23% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 17.79% 60% D- 57% F
Risk Adjusted Return -35.44% 54% F 22% F
Market Capitalization 0.56B 66% D+ 69% C-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.